Organizational Assets
Market Analysis, Private Sector Engagement, and Supply-Demand Dynamics
Across HIV and SRH commodities, Access Bridge conducts market landscaping and segmentation analyses, maps commercial opportunities, identifies systemic barriers, and forecasts supply and demand to understand market functioning and pinpoint opportunities for commercial sector growth. Our team has deep familiarity with the factors that influence demand, affordability, pricing, subsidy levels, and distribution dynamics.
The team has also led efforts to harness private sector strategies for family planning to deliver the DPP. The team engages directly with commercial distributors, manufacturers, and social marketing organizations to strengthen distribution pathways, expand market reach, and identify opportunities to grow the commercial sector.
Government Engagement, Stewardship, and Coordination
AAccess Bridge has deep, durable relationships with Ministries of Health, national technical working groups, Global Fund and PEPFAR country teams, regulatory authorities, prevention program implementers, and civil society organizations across Eastern and Southern Africa. The team helps governments interpret evidence and strengthen stewardship structures to accelerate prevention product introduction. Access Bridge has helped unify fragmented discussions into coherent national plans and fostered accountability and transparency through civil society engagement.
Our team has supported Ministries of Health to develop and operationalize national Total Market Approach (TMA) pathways, particularly in contexts where public sector leadership, stewardship structures, and quantification processes require strengthening. We have supported governments to examine market inefficiencies, clarify sector roles, and develop costed operational plans that consider the delicate balance between free, subsidized, and commercial supplies. Access Bridge has demonstrated capacity to support Ministries of Health to translate market evidence into national plans that reflect realistic procurement volumes, quantification needs, regulatory considerations, and subsidy rationales.
Data Systems and Resource Generation
Access Bridge develops and deploys tools, materials, and frameworks that serve as the foundation for accelerating product introduction and access in priority countries, including:
- The Adaptable Product Introduction Framework, the field's first step-by-step, evidence-based guide to launching new HIV prevention products. The framework sets global benchmarks for speed, equity, user-centered design, and real-world program readiness, and has shaped product rollout planning for CAB, LEN, and the DPP across multiple countries.
- Suite of CAB and LEN rollout materials that guide global and national planning, including: The Plan for CAB; The Plan for LEN; Gears of LEN Rollout and Getting PrEP Rollout Right This Time, which synthesizes lessons from oral PrEP introduction and provides actionable, stakeholder-specific priorities for accelerating LEN access.
- Real-time data systems including PrEPWatch and the Global PrEP Tracker, the only comprehensive, global database tracking PrEP regulatory approvals, implementation science studies, rollout data, and scale-up indicators. PrEPWatch supports governments, donors, researchers, and implementers to monitor progress and make informed policy, programs, and investment decisions.
- Demand-generation aproaches for the DPP, as part of the DPP Consortium, and MK-8527, the monthly PrEP pill, grounded in human-centered design research and extensive validation with potential end users
Convening and Facilitation
A core strength of Access Bridge is its ability to guide and support multi-stakeholder groups. Through years of global, regional, and national conversations, the team has demonstrated an ability to create consensus and help stakeholders identify shared priorities grounded in evidence. Access Bridge has led national dialogues, supported technical working groups, facilitated cross-country communities of practice, and coordinated donor-policymaker discussions via BioPIC, WHO Think Tanks, DPP Consortium, and the LA-PrEP Coalition. Our roles have included:
- Secretariat of the LA-PrEP Coalition: Convene Ministries of Health, donors, product developers, researchers, implementers, and civil society to accelerate rollout of lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR) by linking diverse actors and driving collective action. We have secured transparency commitments from product developers, including pricing information, post-trial access pathways, plans for direct community engagement, and progress toward generic licensing.
- Biomedical Prevention Implementation Collaborative (BioPIC): Bring together Ministries of Health and donors in dedicated convenings, including high-level dialogues to identify challenges, surface country needs, and promote alignment across actors.
- Ministry of Health Community of Practice for all priority LEN introduction countries: Conceptualized and lead this 3-weekly CoP, fostering cross-country learning and problem-solving as countries introduce LEN. In parallel, the team has supported civil society organizations to track rollout progress and engage governments, ensuring accountability and transparency throughout the introduction process.
- Long-Acting PrEP Implementation Science Think Tanks: Co-lead with WHO a long-running Think Tank series that brings together more than 100 global stakeholders to address evidence gaps, implementation challenges, and data needs for introduction of new PrEP products. These Think Tanks have shaped coordinated messaging, informed global policy, and clarified national implementation considerations for rapid rollout.
- DPP Consortium Leadership: As the Secretariat and lead of the DPP Consortium, our team has driven the global effort to prepare for and introduce the DPP, enabling major progress across regulatory guidance, country planning, stakeholder engagement, and delivery systems, including private sector delivery, to position the DPP for introduction. Through this coordination, the consortium has defined a regulatory pathway for multipurpose prevention technologies, advanced HIV/SRH integration at country level, built broad stakeholder buy-in, and generated growing interest in integrated prevention solutions, moving the field closer to offering women a new dual-protection option.
For more information or to partner with us, reach out to admin@healthaccessbridge.org.
